The introduction of artificial intelligence (AI) to assist in performing colonoscopies is associated with a reduction in the ability of healthcare professionals to detect precancerous growths (adenomas) in the colon without the aid of AI, according to an article published in The Lancet Gastroenterology & Hepatology.
In the US, the incidence of colorectal cancer increased in people aged 45-49 years in the period 2019-2022, after advancing the screening age from 50 to 45 years, according to a study published in JAMA. The use of mailed faecal tests made it possible to reach people in this age group, without affecting screening rates in people over 50, says another paper published in the same journal.
Respiratory viruses trigger metastatic breast cancer cells to proliferate in lungs in mouse models of breast cancer, a study in Nature indicates. These findings are supported by human observational data.
Certain immunotherapy treatments for cancer work by releasing the brakes on our defences. However, their response varies and is not uniform in all patients. A team in the United States has now published a study in Nature according to which certain autoantibodies present in patients could improve the efficacy of the therapy, which would explain some of this variability and could be used to design future complementary treatments.
Research estimates that 15.6 million people born between 2008 and 2017 worldwide will develop gastric cancer at some point in their lives if current trends continue. In Spain, there would be 58,641 cases, or 1.24% of people in this age group. The team used data on gastric cancer from 185 countries in 2022 combined with mortality projections based on United Nations demographic data. The estimates, published in the journal Nature Medicine, show that 76% of cases could be attributed to Helicobacter pylori, a common bacterium found in the stomach.
Although tobacco consumption is declining in many parts of the world, there appears to be an increase in the number of lung cancer cases among non-smokers. One of the possible causes of this increase is air pollution. Now, researchers in the US, with Spanish participation, have analysed the genomes of 871 lung tumours in people from various locations who had never smoked. The results, published in the journal Nature, indicate that greater exposure to pollution is linked to an increase in the number of mutations, including those commonly associated with tobacco.
So-called precision oncology involves the use of drugs that target specific molecular alterations in the tumour. These therapies are usually tested in clinical trials in adults and most have not been approved for use in children. An opinion article calls for these trials to be extended to children as well, given the difficulty of conducting such trials in children due to the small number of cases. According to the authors, who publish the text in the journal Trends in Cancer, given that children and adolescents tend to tolerate therapy better than older adults, ‘the time has come to consider age-agnostic approvals, i.e. approvals that include children and adults of any age’.
Research analyzing data from more than 200 countries concludes that people over the age of 65 will face an increase in skin cancer cases over the next two decades. The study, published in JAMA Dermatology, used data from 1990 to 2021 and made estimates through 2050. Men and people living in countries with higher sociodemographic indices showed a higher incidence.
A phase 1 clinical trial has tested the safety and preliminary efficacy of a new form of CAR-T cell therapy - which they call “armed” - in patients with lymphoma. The novelty consists of adding another gene to help increase response. Of the 21 patients treated, all resistant to multiple lines of treatment including approved CAR-T therapies in 20 of them, 81% showed a response and 52% went on to achieve complete remission without significantly greater side effects than with the standard option. The results are published in the journal NEJM.
A study published today in Nature with the participation of the CNIO points to the bacterial toxin colibactin, produced by some strains of Escherichia coli, as a possible culprit in the increase in early-onset colorectal cancer. The study shows that exposure to the toxin during early childhood leaves a genetic signature in colon cells and demonstrates a substantial increase in these mutations in cases of colorectal cancer in people under 50.